Identifying Cancer Stem Cells in Solid Tumors: Case Not Proven

Hewitt HB. A critical examination of the foundations of immunotherapy for cancer. Clin Radiol 1979; 30: 361–9.

Kallman RF, Silini G, Van Putten LM. Factors influencing the quantitative estimation of the in vivo survival of cells from solid tumors. J Natl Cancer Inst 1967; 39: 539–49.

Trott KR. Tumour stem cells: the biological concept and its application in cancer treatment. Radiother Oncol 1994; 30: 1–5.

Hendry JH, West CM, Moore JV, Potten CS. Tumour stem cells: the relevance of predictive assays for tumour control after radiotherapy. Radiother Oncol 1994; 30: 11–6.

Denekamp J. Tumour stem cells: facts, interpretation and consequences. Radiother Oncol 1994; 30: 6–10.

Hill RP, Milas L. The proportion of stem cells in murine tumors. Int J Radiat Oncol Biol Phys 1989; 16: 513–8.

Davidson SE, West CM, Hunter RD. Lack of association between in vitro clonogenic growth of human cervical carcinoma and tumour stage, differentiation, patient age, host cell infiltration or patient survival. Int J Cancer 1992; 50: 10–4.

Wang JC, Dick JE. Cancer stem cells: lessons from leukemia. Trends Cell Biol 2005; 15: 494–501.

Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A 2003; 100: 3983–8.

Singh SK, Hawkins C, Clarke ID, et al. Identification of human brain tumour initiating cells. Nature 2004; 432: 396–401.

Gregory CA, Prockop DJ, Spees JL. Non-hematopoietic bone marrow stem cells: molecular control of expansion and differentiation. Exp Cell Res 2005; 306: 330–5.

Goldman SA, Sim F. Neural progenitor cells of the adult brain. Novartis Found Symp 2005; 265: 66–80; discussion 82–97.

Collins CA, Partridge TA. Self-renewal of the adult skeletal muscle satellite cell. Cell Cycle 2005;1338–41.

Li L, Xie T. Stem cell niche: structure and function. Annu Rev Cell Dev Biol 2005; 21: 605–31.

Ling V, Chambers AF, Harris JF, Hill RP. Dynamic heterogeneity and metastasis. J Cell Physiol Suppl 1984; 3: 99–103.

Hill RP, Chambers AF, Ling V, Harris JF. Dynamic heterogeneity: rapid generation of metastatic variants in mouse B16 melanoma cells. Science 1984; 224: 998–1001.

Jackson AL, Loeb LA. The mutation rate and cancer. Genetics 1998; 148: 1483–90.

Narod SA, Foulkes WD. BRCA1 and BRCA2:1994 and beyond. Nat Rev Cancer 2004; 4: 665–76.

Young SD, Hill RP. Effects of reoxygenation on cells from hypoxic regions of solid tumors: anticancer drug sensitivity and metastatic potential. J Natl Cancer Inst 1990; 82: 371–80.

Zhang L, Hill RP. Hypoxia enhances metastatic efficiency by up-regulating Mdm2 in KHT cells and increasing resistance to apoptosis. Cancer Res 2004; 64: 4180–9.

Bissell MJ, Labarge MA. Context, tissue plasticity, and cancer: are tumor stem cells also regulated by the microenvironment? Cancer Cell 2005; 7: 17–23.

Greijer AE, van der Groep P, Kemming D, et al. Up-regulation of gene expression by hypoxia is mediated predominantly by hypoxia-inducible factor 1 (HIF-1). J Pathol 2005; 206: 291–304.

Leo C, Giaccia AJ, Denko NC. The hypoxic tumor microenvironment and gene expression. Semin Radiat Oncol 2004; 14: 207–14.

Jothy S. CD44 and its partners in metastasis. Clin Exp Metastasis 2003; 20: 195–201.

Singh SK, Clarke ID, Hide T, Dirks PB. Cancer stem cells in nervous system tumors. Oncogene 2004; 23: 7267–73.

Smalley MJ, Clarke RB. The mammary gland “side population”: a putative stem/progenitor cell marker? J Mammary Gland Biol Neoplasia 2005; 10: 37–47.

Patrawala L, Calhoun T, Schneider-Broussard R, Zhou J, Claypool K, Tang DG. Side population is enriched in tumorigenic, stem-like cancer cells, whereas ABCG2+ and ABCG2− cancer cells are similarly tumorigenic. Cancer Res 2005; 65: 6207–19.

Kondo T, Setoguchi T, Taga T. Persistence of a small subpopulation of cancer stem-like cells in the C6 glioma cell line. Proc Natl Acad Sci U S A 2004; 101: 781–6.

Hewitt HB, Blake E, Porter EH. The effect of lethally irradiated cells on the transplantability of murine tumours. Br J Cancer 1973; 28: 123–35.

Peters LJ, Hewitt HB. The influence of fibrin formation on the transplantability of murine tumour cells: implications for the mechanism of the Revesz effect. Br J Cancer 1974; 29: 279–91.

Hill RP. The TD50 assay for tumour cells. In: Edinburgh: Churchill Livingstone; 1985. Potten CS and Hendry JS, editors. Cell clones: manual of mammalian cell techniques.

Sun B, Chen M, Hawks CL, Hornsby PJ. Immortal ALT+ human cells do not require telomerase reverse transcriptase for malignant transformation. Cancer Res 2005; 65: 6512–5.

Lee CH, Xue H, Sutcliffe M, et al. Establishment of subrenal capsule xenografts of primary human ovarian tumors in SCID mice: potential models. Gynecol Oncol 2005; 96: 48–55.

Mullen P. The use of Matrigel to facilitate the establishment of human cancer cell lines as xenografts. Methods Mol Med 2004; 88: 287–92.

Mehta RR, Graves JM, Hart GD, Shilkaitis A, Das Gupta TK. Growth and metastasis of human breast carcinomas with Matrigel in athymic mice. Breast Cancer Res Treat 1993; 25: 65–71.

White AC, Levy JA, McGrath CM. Site-selective growth of a hormone-responsive human breast carcinoma in athymic mice. Cancer Res 1982; 42: 906–12.